Page 286 - Haematologica April 2020

V. Daidone et al.
Suppl 1:24-27.
9. Zheng X, Chung D, Takayama TK.
Structure of von Willebrand factor-cleaving protease (ADAMTS13), a metalloprotease involved in thrombotic thrombocytopenic purpura. J Biol Chem. 2001;276(44):41059- 41063.
10. Dent JA, Berkowitz SD, Ware J, Kasper CK, Ruggeri ZM. Identification of a cleavage site directing the immunochemical detec- tion of molecular abnormalities in type IIA von Willebrand factor. Proc Natl Acad Sci USA. 1990;87(16):6306-6310.
11. Sadler JE, Budde U, Eikenboom JC, et al. Working Party on von Willebrand Disease Classification. Update on the pathophysiol- ogy and classification of von Willebrand disease: a report of the Subcommittee on von Willebrand factor. J Thromb Haemost. 2006;4(10):2103-2114.
12. Goodeve A. The genetic basis of von Willebrand disease. Blood Rev. 2010; 24(3):123-134.
13. Stakiw J, Bowman M, Hegadorn C, et al. The effect of exercise on von Willebrand factor and ADAMTS-13 in individuals with type 1 and type 2B von Willebrand disease. J Thromb Haemost. 2008;6(1):90-96.
14. Pottinger BE, Read RC, Paleolog EM, et al. Von Willebrand factor is an acute phase reactant in man. Thromb Res. 1989;53(4):387–394.
15. Stirling Y, Woolf L, North WR, et al. Hemostasis in normal pregnancy. Thromb Haemost. 1984;52(2):176–182.
16. Daidone V, Galletta E, Casonato A. Type 1 von Willebrand disease due to a vicinal cys- teine loss (p.C524Y) disclosed after a thrombotic episode. Thromb Res. 2018;161:91-93.
17. Daidone V, Gallinaro L, Cattini MG, et al. An apparently silent nucleotide substitu- tion (c.7056C>T) in the von Willebrand fac- tor gene is responsible for type 1 von Willebrand disease. Haematologica. 2011;96(6):881-887.
18. Pagliari MT, Baronciani L, Garcìa Oya I, et al. A synonymous (c.3390C>T) or a splice- site (c.3380-2A>G) mutation causes exon 26 skipping in four patients with von Willebrand disease (2A/IIE). J Thromb Haemost. 2013;11(7):1251-1259.
19. Corrales I, Ramírez L, Altisent C, Parra R, Vidal F. The study of the effect of splicing mutations in von Willebrand factor using RNA isolated from patients’ platelets and leukocytes. J Thromb Haemost. 2011;9(4):679-688.
20. Borràs N, Orriols G, Batlle J, et al. Unraveling the effect of silent, intronic and missense mutations on VWF splicing: con- tribution of next generation sequencing in the study of mRNA. Haematologica.
2019;104(3):587-598.
21. Rodeghiero F, Tosetto A, Abshire T, et al.
on behalf of the ISTH/SSC Joint VWF and Perinatal/Pediatric Hemostasis Subcommittees Working Group. ISTH/SSC Bleeding Assessment Tool: a standardized questionnaire and a proposal for a new bleeding score for inherited bleeding disor- ders. J Thromb Haemost. 2010;8(9):2063– 2065.
22. Casonato A, Pontara E, Sartorello F, et al. Reduced von Willebrand factor survival in type Vicenza von Willebrand disease. Blood. 2002;99(1):180-184.
23. Casonato A, Pontara E, Sartorello F, et al. Identifying carriers of type 2N von Willebrand disease: procedures and signifi- cance. Clin Appl Thromb Hemost. 2007;13(2):194-200.
24. Casonato A, Pontara E, Sartorello F, et al. Identifying type Vicenza von Willebrand disease. J Lab Clin Med. 2006;147(2):96- 102.
25. Casonato A, Pontara E, Boscaro M, et al. Abnormalities of von Willebrand factor are also part of the prothrombotic state of Cushing’s syndrome. Blood Coagul Fibrinolysis. 1999;10(3):145-151.
26. Gallinaro L, Cattini MG, Sztukowska M, et al. A shorter von Willebrand factor sur- vival in O blood group subjects explains how ABO determinants influence plasma von Willebrand factor. Blood. 2008; 111(7):3540-3545.
27. Casonato A, Pontara E, Doria A, et al. Lack of multimer organization of von Willebrand factor in an acquired von Willebrand syndrome. Br J Haematol. 2002; 116(4):899-904.
28. Casonato A, Pontara E, Doria A, et al. An Arg760Cys mutation in the consensus sequence of the von Willebrand factor propeptide cleavage site is responsible for a new von Willebrand disease variant. Blood. 2003;101(1):151-156.
29. Baronciani L, Cozzi G, Canciani MT, et al. Molecular defects in type 3 von Willebrand disease: updated results from 40 multieth- nic patients. Blood Cells Mol Dis. 2003; 30(3):264-270.
30. Rehemtulla A, Kaufman RJ. Preferred sequence requirements for cleavage of pro- von Willebrand factor by propeptide-process- ing enzymes. Blood. 1992;79(9):2349-2355.
31. Platè M, Duga S, Baronciani L, et al. Premature termination codon mutations in the von Willebrand factor gene are associat- ed with allele-specific and position-depen- dent mRNA decay. Haematologica. 2010; 95(1):172–174.
32. Casonato A, Galletta E, Sarolo L, Daidone V. Type 2N von Willebrand disease: Characterization and diagnostic difficul-
ties. Haemophilia. 2018;24(1):134-140.
33. Casonato A, Pontara E, Battiston M, et al. C2362F mutation gives rise to an ADAMTS13-resistant von Willebrand fac- tor. Thromb Haemost. 2013;109(6):999-
1006.
34. Daidone V, Saga G, Barbon G, et al. The
p.R1819_C1948delinsS mutation makes von Willebrand factor ADAMTS13-resis- tant and reduces its collagen-binding capac- ity. Br J Haematol. 2015;170(4):564-573.
35. Tsai HM, Nagel RL, Hatcher VB, Sussman II. Multimeric composition of endothelial cell-derived von Willebrand factor. Blood. 1989;73(8):2074-2076.
36. Dong JF, Moake JL, Nolasco L, et al. ADAMTS-13 rapidly cleaves newly secret- ed ultralarge von Willebrand factor multi- mers on the endothelial surface under flow- ing conditions. Blood. 2002;100(12):4033- 4039.
37. De Ceunynck K, De Meyer SF, Vanhoorelbeke K. Unwinding the von Willebrand factor strings puzzle. Blood. 2013;121(2):270-277.
38. Crawley JT, de Groot R, Xiang Y, Luken BM, Lane DA. Unraveling the scissile bond: how ADAMTS13 recognizes and cleaves von Willebrand factor. Blood. 2011; 118(12):3212-3221.
39. Turner NA, Nolasco L, Ruggeri ZM, Moake JL. Endothelial cell ADAMTS-13 and VWF: production, release, and VWF string cleav- age. Blood. 2009;114(24):5102-5111.
40. Michaux G, Pullen TJ, Haberichter SL, Cutler DF. P-selectin binds to the D’-D3 domains of von Willebrand factor in Weibel-Palade bodies. Blood. 2006; 107(10):3922-3924.
41. Solimando M, Baronciani L, La Marca S, et al. Molecular characterization, recombi- nant protein expression, and mRNA analy- sis of type 3 von Willebrand disease: Studies of an Italian cohort of 10 patients. Am J Hematol. 2012;87(9):870-874.
42. Galletta E, Daidone V, Zanon E, Casonato S. Type 3 von Willebrand disease mistaken for moderate haemophilia A: a lesson still to be learned. Haemophilia. 2018; 24(3):154-157.
43. Casonato A, Cattini MG, Barbon G, Daidone V, Pontara E. Severe, recessive type 1 is a discrete form of von Willebrand disease: the lesson learned from the c.1534- 3C>A von Willebrand factor mutation. Thromb Res. 2015;136(3):682-686.
44. Burset M, Seledtsov IA, Solovyev VV. Analysis of canonical and non-canonical splice sites in mammalian genomes. Nucleic Acids Res. 2000;28(21):4364-4375.
45. Sibley CR, Blazquez L, Ule J. Lessons from non-canonical splicing. Nat Rev Genet. 2016;17(7):407-421.
1128
haematologica | 2020; 105(4)